Blood-based liquid biopsy: Venous blood sample will be taken from the patient as part of the routine blood tests taken as part of the work at the Medical Center
Study summary
The purpose of the researchers is to test whether the CancerenD24 index, an algorithm based on the quantitative value of CD24, CD11b, clinical and laboratory characteristics, developed in the laboratory can help in the early detection of a malignant disease in a population of healthy subjects.
Eligibility
Sex
ALL
Min age
40 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria:
1. Completion of all medical exams and questionnaires including cancer diagnoses, demographic data and other epidemiologic information
2. Willing and able to sign an informed consent
3. Age ≥40 years
Exclusion Criteria:
1. Age \< 40 years
2. Pregnancy or breastfeeding
3. Any type of fever
4. Any cancer active at study entry or up to 5 years prior to study entry
5. Polyposis syndromes
6. Inflammatory bowel disease
7. Unwilling or unable to provide informed consent
Primary outcome measure(s)
Evaluation of the CancerenD24 Screening Assay — 3 years To evaluate the "CancerenD24 screening assay" as an aid to physicians in diagnosing cancer in subjects aged 40 years and above
Trial sites (1)
Facility
City
Region
Status
Integrated Cancer Prevention Center at the Tel Aviv Sourasky Medical Center Ichilov
Tel Aviv
Israel
Recruiting
More Tel-Aviv Sourasky Medical Center trials in Israel
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
